Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/35508972http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/35508972http://www.w3.org/2000/01/rdf-schema#comment"

Background

Receptor-interacting protein kinase 2 (RIPK2, also known as RIP2) was reported to be associated with bacterial infections as well as inflammatory responses. However, the role of RIPK2 in prognosis and immunotherapy response is yet to be elucidated in human pan-cancer.

Methods

In this study, we investigated the expression, gene alteration landscape and prognostic value of RIPK2 in 33 cancers through various databases including Ualcan, cBioportal and Gene Expression Profiling Interactive Analysis 2 (GEPIA2). Then, the correlation between RIPK2 and immune infiltration, immune score, stromal score, and ESTIMATE score was investigated in the Cancer Genome Atlas (TCGA) and tumor immune estimation resource (TIMER) databases. Independent cohorts were utilized to explore the role of RIPK2 in tumor immunotherapy response. Furthermore, Gene set enrichment analysis (GSEA) was conducted to explore the mechanisms by which RIPK2 regulates immune therapy resistance. Single-cell RNA-seq datasets were used to analyze the expression level of RIPK2 on different immune cells. Moreover, CellMiner database was used to explore the relationship between RIPK2 expression with drug response.

Result

Compared with normal tissue, tumor tissue had a higher expression level of RIPK2 in various cancers. Survival analysis showed that high expression of RIPK2 associated with poor prognosis in numerous cancers. RIPK2 was found to promote a series of immune cell infiltration and B cells, macrophages, and neutrophils were significantly positively correlated with the expression of RIPK2. Moreover, RIPK2 affected immune score, stromal score and ESTIMATE score for a wide range of cancers. In the vast majority of 33 cancers, gene co-expression analysis showed that RIPK2 was positively correlated with the expression of immune checkpoint markers, such as PDCD1 (PD-1), CD274 (PD-L1), CTLA4 and TIGIT. RIPK2 aggravated cytotoxic T lymphocyte (CTL) dysfunction and related to the poor efficacy of immune checkpoint blockade in skin cutaneous melanoma (SKCM) and kidney renal clear cell carcinoma (KIRC). High expression of RIPK2 promoted innate immunotherapy resistance and adaptive immunotherapy resistance through IL-6/JAK/STAT3 signaling, interferon-gamma response, and interferon-alpha response pathway.

Conclusions

These results confirmed that RIPK2 could serve as a prognostic biomarker and promoted immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction."xsd:string
http://purl.uniprot.org/citations/35508972http://purl.org/dc/terms/identifier"doi:10.1186/s10020-022-00475-8"xsd:string
http://purl.uniprot.org/citations/35508972http://purl.uniprot.org/core/author"Du Y."xsd:string
http://purl.uniprot.org/citations/35508972http://purl.uniprot.org/core/author"Liu X."xsd:string
http://purl.uniprot.org/citations/35508972http://purl.uniprot.org/core/author"Song J."xsd:string
http://purl.uniprot.org/citations/35508972http://purl.uniprot.org/core/author"Yang R."xsd:string
http://purl.uniprot.org/citations/35508972http://purl.uniprot.org/core/author"He P."xsd:string
http://purl.uniprot.org/citations/35508972http://purl.uniprot.org/core/author"Wei R."xsd:string
http://purl.uniprot.org/citations/35508972http://purl.uniprot.org/core/date"2022"xsd:gYear
http://purl.uniprot.org/citations/35508972http://purl.uniprot.org/core/name"Mol Med"xsd:string
http://purl.uniprot.org/citations/35508972http://purl.uniprot.org/core/pages"47"xsd:string
http://purl.uniprot.org/citations/35508972http://purl.uniprot.org/core/title"Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction."xsd:string
http://purl.uniprot.org/citations/35508972http://purl.uniprot.org/core/volume"28"xsd:string
http://purl.uniprot.org/citations/35508972http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/35508972
http://purl.uniprot.org/citations/35508972http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/35508972
http://purl.uniprot.org/uniprot/#_A0A0S2Z4Z8-mappedCitation-35508972http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35508972
http://purl.uniprot.org/uniprot/#_B3KQM3-mappedCitation-35508972http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35508972
http://purl.uniprot.org/uniprot/#_E7ERW9-mappedCitation-35508972http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35508972
http://purl.uniprot.org/uniprot/#_Q2TU65-mappedCitation-35508972http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35508972
http://purl.uniprot.org/uniprot/#_O43353-mappedCitation-35508972http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35508972
http://purl.uniprot.org/uniprot/#_Q6Q322-mappedCitation-35508972http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35508972
http://purl.uniprot.org/uniprot/Q2TU65http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/35508972
http://purl.uniprot.org/uniprot/O43353http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/35508972
http://purl.uniprot.org/uniprot/E7ERW9http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/35508972
▶